We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Serum MicroRNA Panel Predict P-Tau/Aβ42 in CSF in Alzheimer's Disease

By LabMedica International staff writers
Posted on 29 Nov 2021
Print article
Image: The miRNeasy Serum/Plasma Kit: For purification of cell-free total RNA, including miRNA, from human plasma and serum (Photo courtesy of Qiagen)
Image: The miRNeasy Serum/Plasma Kit: For purification of cell-free total RNA, including miRNA, from human plasma and serum (Photo courtesy of Qiagen)
Amyloid β (Aβ) and tau pathologies are classic characteristic features of Alzheimer’s disease (AD), and they are widely used as diagnostic biomarkers. AD pathology is characterized by the accumulation of amyloid-β (Aβ) plaques and tau neurofibrillary tangles in the brain.

Aβ and tau in samples of CSF obtained from patients has been shown to diagnose AD with excellent accuracy. Multiple studies have suggested that the combined measurements of phosphorylated-tau (P-tau) and Aβ42 in the CSF can inform a more accurate diagnosis than either test alone.

A team of Neurologists at the Capital Medical University (Beijing, China) extracted RNA samples from the participant's blood. P-tau/Aβ42 of CSF was examined for diagnostic purposes. A pilot study (controls, 21; AD, 23), followed by second (controls, 216; AD, 190) and third groups (controls, 153; AD, 151), was used to establish and verify a predictive model of P-tau/Aβ42 in CSF. The test was then applied to a fourth group of patients with different dementias: AD,155; amnestic mild cognitive impairment (aMCI), 55; vascular dementia (VaD), 51; Parkinson disease dementia (PDD), 53; behavioral variant frontotemporal dementia (bvFTD), 53; dementia with Lewy body (DLB), 52) and 139 controls, to assess its diagnostic capacity

The levels of Aβ42, total-tau (T-tau), and P-tau (tau phosphorylated at Thr 181) in the CSF were then measured using an INNOTEST enzyme-linked immunosorbent assay (ELISA) kits (Fujirebio Diagnostics, Tokyo; Japan). Total RNA was isolated using the miRNeasy Serum Kit (Qiagen, Germantown, MD,USA). For the preparation of the sequencing library, the team used 1 μg of total RNA quantified with Nano Drop 8000 (Thermo Fisher Scientific, Waltham, MA, USA) and Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA).

The investigators reported that in the pilot study, 29 upregulated and 31 downregulated miRNAs in the AD group were found. In Dataset 2, these miRNAs were then included as independent variables in the linear regression model. A seven-microRNA panel (miR-139-3p, miR-143-3p, miR-146a-5p, miR-485-5p, miR-10a-5P, miR-26b-5p, and miR-451a-5p) accurately predicted values of P-tau/Aβ42 of CSF. In Datasets 3 and 4, by applying the predicted P-tau/Aβ42, the predictive model successfully differentiates AD from controls and VaD, PDD, bvFTD, and DLB.

The authors concluded that the results of their study indicate that a panel of seven miRNAs are potential blood biomarkers for AD. Specifically, the association between the levels of seven miRNAs and the P-tau/Aβ42 ratio in the CSF of AD patients confirms that miRNA biomarkers may reflect pathological changes in the brain and, therefore, can inform the identification of patients with AD. The study was published on November 15, 2021 in the journal BMC Medicine.

Related Links:
Capital Medical University
Fujirebio Diagnostics
Qiagen
Thermo Fisher Scientific
Agilent Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.